| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trial |
Servizio di Medicina Nucleare, Ospedale M. Bufalini, 47023 Cesena, Italy [M. S., G. M., P. R.]; Division of Neurosurgery Di.S.C.A.T. Department of Surgery, University of Genoa, Medical School, 16132 Genoa, Italy [G. L. V.]; Philogen S.r.l., 53100 Siena, Italy [L. G., G. N., F. V., A. L.]; Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy [L. B., P. C., L. Z.]; Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, CH-8057 Zurich, Switzerland [D. N.]; and Istituto Oncologico Romagnolo, Forlì, Italy [P. R.]
Purpose: ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling. We demonstrated previously the possibility to target and selectively deliver therapeutic substances to tumor vasculature in experimental animal models using a human recombinant antibody fragment, L19, specific for the ED-B domain of fibronectin. Here we evaluate the possibility of targeting primary tumors and metastatic lesions in cancer patients through immunoscintigraphy using 123I-labeled dimeric L19 [L19(scFv)2].
Experimental Design: Twenty patients (34–79 years of age) with lung, colorectal, or brain cancer, whose tumors had been confirmed by imaging techniques and/or histologically, were admitted to the immunoscintigraphic investigation.
Results: The dimeric L19 antibody selectively localized in tumor lesions in aggressive types of lung cancer and colorectal cancer. Because ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling, L19(scFv)2 is able to distinguish between quiescent and actively growing lesions. No side effects were observed.
Conclusions: The ability of L19(scFv)2 to target tumors in patients provides the foundations for new therapeutic applications, in which the L19 antibody is engineered to selectively deliver bioactive molecules to primary tumors as well as to metastases.
This article has been cited by other articles:
|
|
 |
|
  C. Schliemann, A. Palumbo, K. Zuberbuhler, A. Villa, M. Kaspar, E. Trachsel, W. Klapper, H. D. Menssen, and D. Neri Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 Blood, March 5, 2009; 113(10): 2275 - 2283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sauer, P. A. Erba, M. Petrini, A. Menrad, L. Giovannoni, C. Grana, B. Hirsch, L. Zardi, G. Paganelli, G. Mariani, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients Blood, March 5, 2009; 113(10): 2265 - 2274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. W. Karuri, Z. Lin, H. S. Rye, and J. E. Schwarzbauer Probing the Conformation of the Fibronectin III1-2 Domain by Fluorescence Resonance Energy Transfer J. Biol. Chem., February 6, 2009; 284(6): 3445 - 3452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Wu Antibodies and Antimatter: The Resurgence of Immuno-PET J. Nucl. Med., January 1, 2009; 50(1): 2 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Marlind, M. Kaspar, E. Trachsel, R. Sommavilla, S. Hindle, C. Bacci, L. Giovannoni, and D. Neri Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy Clin. Cancer Res., October 15, 2008; 14(20): 6515 - 6524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wagner, P. Schulz, A. Scholz, B. Wiedenmann, and A. Menrad The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer Clin. Cancer Res., August 1, 2008; 14(15): 4951 - 4960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Kaye Bevacizumab for the Treatment of Epithelial Ovarian Cancer: Will This Be Its Finest Hour? J. Clin. Oncol., November 20, 2007; 25(33): 5150 - 5152. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-N. Rybak, C. Roesli, M. Kaspar, A. Villa, and D. Neri The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases Cancer Res., November 15, 2007; 67(22): 10948 - 10957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rossin, D. Berndorff, M. Friebe, L. M. Dinkelborg, and M. J. Welch Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin J. Nucl. Med., July 1, 2007; 48(7): 1172 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Wester Nuclear Imaging Probes: from Bench to Bedside Clin. Cancer Res., June 15, 2007; 13(12): 3470 - 3481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaspar, E. Trachsel, and D. Neri The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis Cancer Res., May 15, 2007; 67(10): 4940 - 4948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. von Lukowicz, M. Silacci, M. T. Wyss, E. Trachsel, C. Lohmann, A. Buck, T. F. Luscher, D. Neri, and C. M. Matter Human Antibody Against C Domain of Tenascin-C Visualizes Murine Atherosclerotic Plaques Ex Vivo J. Nucl. Med., April 1, 2007; 48(4): 582 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Wyss, N. Spaeth, G. Biollaz, J. Pahnke, P. Alessi, E. Trachsel, V. Treyer, B. Weber, D. Neri, and A. Buck Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 Gliomas and Correlation with 131I-SIP(L19), a Marker of Angiogenesis J. Nucl. Med., April 1, 2007; 48(4): 608 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Cai, T. Olafsen, X. Zhang, Q. Cao, S. S. Gambhir, L. E. Williams, A. M. Wu, and X. Chen PET Imaging of Colorectal Cancer in Xenograft-Bearing Mice by Use of an 18F-Labeled T84.66 Anti-Carcinoembryonic Antigen Diabody J. Nucl. Med., February 1, 2007; 48(2): 304 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kenanova, T. Olafsen, L. E. Williams, N. H. Ruel, J. Longmate, P. J. Yazaki, J. E. Shively, D. Colcher, A. A. Raubitschek, and A. M. Wu Radioiodinated versus Radiometal-Labeled Anti-Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments: Optimal Pharmacokinetics for Therapy Cancer Res., January 15, 2007; 67(2): 718 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Berndorff, S. Borkowski, D. Moosmayer, F. Viti, B. Muller-Tiemann, S. Sieger, M. Friebe, C. S. Hilger, L. Zardi, D. Neri, et al. Imaging of Tumor Angiogenesis Using 99mTc-Labeled Human Recombinant Anti-ED-B Fibronectin Antibody Fragments J. Nucl. Med., October 1, 2006; 47(10): 1707 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Silacci, S. S. Brack, N. Spath, A. Buck, S. Hillinger, S. Arni, W. Weder, L. Zardi, and D. Neri Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo Protein Eng. Des. Sel., October 1, 2006; 19(10): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Moosmayer, D. Berndorff, C.-H. Chang, R. M. Sharkey, A. Rother, S. Borkowski, E. A. Rossi, W. J. McBride, T. M. Cardillo, D. M. Goldenberg, et al. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin. Cancer Res., September 15, 2006; 12(18): 5587 - 5595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Xiong, A. Natarajan, X.-B. Shi, G. L. Denardo, and S. J. Denardo Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding Protein Eng. Des. Sel., August 1, 2006; 19(8): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Tijink, D. Neri, C. R. Leemans, M. Budde, L. M. Dinkelborg, M. Stigter-van Walsum, L. Zardi, and G. A.M.S. van Dongen Radioimmunotherapy of Head and Neck Cancer Xenografts Using 131I-Labeled Antibody L19-SIP for Selective Targeting of Tumor Vasculature J. Nucl. Med., July 1, 2006; 47(7): 1127 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Brack, M. Silacci, M. Birchler, and D. Neri Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin. Cancer Res., May 15, 2006; 12(10): 3200 - 3208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Orlova, M. Magnusson, T. L.J. Eriksson, M. Nilsson, B. Larsson, I. Hoiden-Guthenberg, C. Widstrom, J. Carlsson, V. Tolmachev, S. Stahl, et al. Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule. Cancer Res., April 15, 2006; 66(8): 4339 - 4348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Balza, L. Mortara, F. Sassi, S. Monteghirfo, B. Carnemolla, P. Castellani, D. Neri, R. S. Accolla, L. Zardi, and L. Borsi Targeted Delivery of Tumor Necrosis Factor-{alpha} to Tumor Vessels Induces a Therapeutic T Cell-Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin Clin. Cancer Res., April 15, 2006; 12(8): 2575 - 2582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K.E. Borjesson, Y. W.S. Jauw, R. Boellaard, R. de Bree, E. F.I. Comans, J. C. Roos, J. A. Castelijns, M. J.W.D. Vosjan, J. A. Kummer, C. R. Leemans, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody u36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer Res., April 1, 2006; 12(7): 2133 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Berndorff, S. Borkowski, S. Sieger, A. Rother, M. Friebe, F. Viti, C. S. Hilger, J. E. Cyr, and L. M. Dinkelborg Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate Clin. Cancer Res., October 1, 2005; 11(19): 7053s - 7063s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Roodink, J. Raats, B. van der Zwaag, K. Verrijp, B. Kusters, H. van Bokhoven, M. Linkels, R. M.W. de Waal, and W. P.J. Leenders Plexin D1 Expression Is Induced on Tumor Vasculature and Tumor Cells: A Novel Target for Diagnosis and Therapy? Cancer Res., September 15, 2005; 65(18): 8317 - 8323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Miller, H. H. Pien, D. Sahani, A. G. Sorensen, and J. H. Thrall Imaging Angiogenesis: Applications and Potential for Drug Development J Natl Cancer Inst, February 2, 2005; 97(3): 172 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Matter, P. K. Schuler, P. Alessi, P. Meier, R. Ricci, D. Zhang, C. Halin, P. Castellani, L. Zardi, C. K. Hofer, et al. Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin Circ. Res., December 10, 2004; 95(12): 1225 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Venables Aberrant and Alternative Splicing in Cancer Cancer Res., November 1, 2004; 64(21): 7647 - 7654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Olafsen, C.-w. Cheung, P. J. Yazaki, L. Li, G. Sundaresan, S. S. Gambhir, M. A. Sherman, L. E. Williams, J. E. Shively, A. A. Raubitschek, et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications Protein Eng. Des. Sel., January 1, 2004; 17(1): 21 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Borsi, E. Balza, B. Carnemolla, F. Sassi, P. Castellani, A. Berndt, H. Kosmehl, A. Biro, A. Siri, P. Orecchia, et al. Selective targeted delivery of TNF{alpha} to tumor blood vessels Blood, December 15, 2003; 102(13): 4384 - 4392. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
